During the corresponding time, Nuwellis Inc recorded a revenue increase by 14.14 % year on year, sequentially revenue fell by -18.06 %. While revenue at the Nuwellis Inc 's corporate clients
Nuwellis Inc's Comment on Sales, Marketing and Customers
The Aquadex System is used to treat patients with fluid overload, particularly those with heart failure (HF) and refractory acute decompensated heart failure (ADHF). It has been utilized in community-based regional hospitals and single-center studies, demonstrating outcomes such as reduced rehospitalizations for heart failure, significant volume and weight loss, stable renal function, and shorter hospital stays. The system allows medical practitioners to control fluid removal on an individual patient basis and can be administered through peripheral or central venous access.
In the ever-evolving landscape of medical technology, advancements that significantly impact patient outcomes are celebrated as monumental achievements. Nuwellis, Inc. (Nasdaq: NUWE), a company renowned for its dedication to transforming lives through innovative solutions for fluid overload, has recently reached such an achievement. The company proudly announced the first commercial sale of QUELIMMUNE, a groundbreaking therapy developed by SeaStar Medical Holding Corporation. This pivotal sale was made to Cincinnati Children s Hospital, a renowned institution in pediatric care. QUELIMMUNE: A Revolutionary TherapyQUELIMMUNE is designed specifically for pediatric patients who are battling an uncontrolled infla...
In a landmark move, medical technology company Nuwellis Inc. has announced an extension of its supply and collaboration agreement with DaVita, marking an important milestone in the pilot collaboration for Aquadex Ultrafiltration Therapy. This therapy is aimed at adult patients suffering from Congestive Heart Failure (CHF), a chronic condition affecting millions of individuals worldwide. The extension grants Nuwellis an opportunity to continue its groundbreaking efforts towards revolutionizing CHF treatment until August 31, 2024. Furthermore, despite facing lingering market challenges, Nuwellis has managed to demonstrate commendable revenue growth, positioning itself as a prominent player in the healthcare in...
Nuwellis, a leading medical technology company dedicated to improving the lives of people suffering from fluid overload, has recently announced the expansion of its ultrafiltration program to include pediatric patients at one of the largest hospital networks in Florida. This significant development represents the network s commitment to providing advanced medical solutions for a broader range of patients, extending beyond current heart failure and critical care cases.The pediatric ultrafiltration program will utilize Nuwellis innovative Aquadex SmartFlow System, which is designed to effectively remove excess fluid from the body. This non-invasive and gentle approach to fluid removal is particularly benefici...
Nuwellis Inc’s Comment on Sales, Marketing and Customers
The Aquadex System is used to treat patients with fluid overload, particularly those with heart failure (HF) and refractory acute decompensated heart failure (ADHF). It has been utilized in community-based regional hospitals and single-center studies, demonstrating outcomes such as reduced rehospitalizations for heart failure, significant volume and weight loss, stable renal function, and shorter hospital stays. The system allows medical practitioners to control fluid removal on an individual patient basis and can be administered through peripheral or central venous access.
Sources:
Nuwellis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nuwellis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Nuwellis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
222.04 %